Supportive Care

Delaying medication processing is common, especially when it comes to oral cancer therapies. Oncologists at 3 oncology clinics looked at such barriers and the potential impact on patient outcomes.
Most oncologists’ knowledge about toxicities associated with newer therapies comes mainly from clinical trials, but publications of clinical trial safety results may be misleading, according to a study presented by Paolo Bossi, MD, at the recent European Society for Medical Oncology Congress.
Patients receiving allogeneic hematopoietic stem-cell transplant (HSCT) have high rates of vancomycin-resistant enterococci (VRE) upon admission for transplantation.
Adherence to infusional or injectable anticancer drugs is not problematic—as long as the patient gets the infusion or injection, adherence is assured—but adherence is an emerging problem with newer oral anticancer drugs.

San Francisco, CA—Many patients with advanced melanoma or advanced lung cancer have benefited from treatment with checkpoint inhibitors, which have helped extend survival to previously unthinkable lengths. Although the impression is that checkpoint inhibitors are free of adverse events, in reality, clinicians strive daily to balance the efficacy and toxicity of these treatments.

Adelaide, Australia—Prophylactic probiotics can potentially prevent radiation enteropathy, according to research presented by Matthew A. Ciorba, MD, Assistant Professor of Medicine, Division of Gastroenterology, Washing­ton Uni­versity School of Medicine, St. Louis, MO, at the 2016 Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology Annual Meeting on Supportive Care in Cancer.

Adelaide, Australia—SGX942, a novel agent that is first in its class, decreased the incidence of severe oral mucositis in patients with head and neck cancer undergoing chemoradiation, according to new research led by Oreola Donini, PhD, Senior Vice President and Chief Scientific Officer, Soligenix, Princeton, NJ, and Mahesh R. Kudrimoti, MD, Professor of Radiation Medicine, University of Kentucky, Lexington.

Delirium is an exceedingly prevalent syndrome among patients with cancer, but is underrecognized and undertreated, according to Alan Valentine, MD, Chair, Department of Psychiatry, The University of Texas M.D. Anderson Cancer Center, Houston, and Darryl Etter, PsyD, Clinical Psychologist, VA Eastern Colorado Health Care System, Denver, at a webinar hosted by the American Psychosocial Oncology Society in July 2016.

Adelaide, Australia—Nausea is part of a symptom cluster associated with chemotherapy, but the experience of nausea may be a symptom cluster in and of itself, according to a study presented by Ian Olver, MD, President of the Multinational Association of Supportive Care in Cancer (MASCC), Director of the Sansom Institute for Health Research, and Professor of Translational Cancer Research, University of South Australia, Adelaide, at the 2016 MASCC/International Society of Oral Oncology Annual Meeting on Supportive Care in Cancer.

Adelaide, Australia—Stomatitis is a dose-limiting toxicity associated with the use of mammalian target of rapamycin (mTOR) inhibitors, but new treatments can improve quality of life for patients suffering from this often debilitating condition, according to data presented at the 2016 Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology Annual Meeting on Supportive Care in Cancer.

Page 1 of 8
Results 1 - 10 of 76